Malignant Intestinal Obstruction Clinical Trial
Official title:
Prospective Study to Assess the Efficacy and Safety of Lanreotide 120 mg as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients
The primary objective of this study is to assess the efficacy of Lanreotide 120 mg for the
relief of clinical symptoms due to malignant bowel obstruction in inoperable patients. This
effect will be evaluated by the percentage of responder patients 7 and 14 days after one
administration of lanreotide 120 mg.
(A responder patient will be defined either as a patient experiencing < or= 1 vomiting
episode per day during at least three consecutive days or as a patient in whom NGT has been
removed without any vomiting recurrence during at least three consecutive days)
The total number of visits will depend on the clinical situation, 5 visits are obligatory:
Day(D)-3/-0,Day 1,Day 7,Day 14,Day 28
Inclusion visit (D-3/-0): eligibility, PIC, obstruction history, clinical exam, vital signs,
diary cards, VAS scale, cc medication, blood sample
Visit D1: injection Visit D7/D14/28: clinical exam, nutrition procedure, result of
biochemical analyse, adverse events, cc medication
In between the visits, the patient will keep and fill out his diary and VAS scale
| Status | Completed |
| Enrollment | 40 |
| Est. completion date | July 2013 |
| Est. primary completion date | July 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - PIC - >= 18 years at time of enrolment - Diagnosis of a digestive obstruction of malignant origin - Diagnosis of peritoneal carcinomatosis confirmed by a ct scan within the previous 3 months - Inoperability as decided after surgical consultation Exclusion Criteria: - Operable obstruction - Bowel obstruction that can be explained by a non malignant cause - Signs of bowel obstruction - Prior treatment with somatostatin analogues within the previous 60 days - Known hypersensitivity to any of the test materials or related compounds - Previous enrolment in this study |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Belgium | University Hospital Ghent | Ghent |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Ghent |
Belgium,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of responder patients. | At day 7 and day 14. | No | |
| Secondary | Number of daily vomiting episodes on diary cards or measurements of the daily drainage by naso gastric tube (NGT). | day 7, day 14 and day 28 after administration of Lanreotide | No | |
| Secondary | Number of days without vomiting episodes | day 7, day 14 and day 28 after administration of Lanreotide | No | |
| Secondary | Number of daily nausea episodes recorded on diary cards. | day 7, day 14 and day 28 after administration of Lanreotide | No | |
| Secondary | Intensity of abdominal pain assessed on a visual analogue scale. | day 7, day 14 and day 28 after administration of Lanreotide. | No | |
| Secondary | Well-being assessed on a visual analogue scale. | day 7, day 14 and day 28 after administration of Lanreotide. | No | |
| Secondary | Time between first injection and clinical response. | day 7, day 14 and day 28 after administration of Lanreotide | No | |
| Secondary | Clinical and biological adverse events. | day 7, day 14 and day 28 after administration of Lanreotide. | Yes |